CSPC Pharmaceutical Group news

Latest news

• 
  Big Pharma Is Pouring Billions Into China’s Biotechs (opens in a new tab)

  Barrons.com · Sep 14, 2026

• 
  The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight (opens in a new tab)

  PR Newswire · Jun 1, 2026

• 
  CSPC’s SYS6051 Trial Approval Adds New Angle To Valuation Story (opens in a new tab)

  Simply Wall St. · Apr 22, 2026

• 
  2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation (opens in a new tab)

  PR Newswire · Apr 22, 2026

• 
  Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint (opens in a new tab)

  PR Newswire · Apr 1, 2026

• 
  How Regulatory Approval for CSPC Pharmaceutical’s First C5 siRNA Therapy (SEHK:1093) Has Changed Its Investment Story (opens in a new tab)

  Simply Wall St. · Nov 7, 2025

• 
  Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates (opens in a new tab)

  GlobeNewswire · Nov 4, 2025

• 
  How Dual U.S. and China Trial Approvals for SYH2070 Could Shape CSPC (SEHK:1093) Investors' Outlook (opens in a new tab)

  Simply Wall St. · Oct 13, 2025